Fanconi Anemia Complementation Group A C3469521
A genetic disorder causing bone marrow failure, birth defects, and high cancer risk. Treatment may include bone marrow transplant, supportive care, and regular cancer monitoring.
Key facts at a glance
- ICD-10
- D61.03
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Bone marrow failure
(hematologic)Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Skin hyperpigmentation
(integumentary)Microcephaly
(neurologic)Renal anomalies
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Hematopoietic Stem Cell Transplantation
Allogeneic HSCT remains the only established curative option for Fanconi anemia group A with bone marrow failure. Careful conditioning regimens accounting for FA's heightened chemotherapy sensitivity are essential.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Androgen Therapy
Oxymetholone or similar androgens can improve blood counts in FA patients with marrow failure who are not transplant candidates. Response rates vary and treatment may lose efficacy over time.
Additional treatment options
Gene Therapy
Experimental gene therapy aims to correct the FANCA gene defect using viral vectors to introduce functional copies of the gene into hematopoietic stem cells.
procedureSurveillance for Malignancy
FA patients have significantly elevated risk of head and neck squamous cell carcinoma and other malignancies. Regular screening and vigilance for suspicious lesions is critical.
monitoringInfection Prevention
Strict hand hygiene, avoiding crowds during immunosuppression, and prophylactic antibiotics during neutropenic periods help prevent serious infections.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Fanconi Anemia Complementation Group A C3469521?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Fanconi Anemia Complementation Group A C3469521. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy